›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Tempus xF Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TempusType:
Laboratory Developed Test
Related tests:
Tempus xF, a liquid biopsy cell-free DNA assay that analyzes 77 genes, to its sequencing capabilities. Its is a non-invasive genomic sequencing panel. The assay is capable of detecting mutations in two variant classes in ~105 genes, including: Single Nucleotide Variants (SNVs) and insertions and deletions (indels), as well as Copy Number Amplifications (CNAs) in 6 genes, Copy Number Deletions (CNDs) in 2 genes,* and gene rearrangements (translocations) in 7 genes spanning ~0.3 Mb of genomic space. Microsatellite Instability High (MSI-H) status is also reported when detected. The panel is designed to provide clinical decision support for patients with solid tumors and is focused on the identification of oncologic, including resistance, mutations.
Cancer:
Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), ATR (Ataxia telangiectasia and Rad3-related protein), BAP1 (BRCA1 Associated Protein 1), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BTK (Bruton Tyrosine Kinase), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCND3 (Cyclin D3), CDH1 (Cadherin 1), CDK1 (Cyclin-dependent kinase 1), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), DDR2 (Discoidin domain receptor 2), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FGFR (Fibroblast Growth Factor Receptor), FLT3 (Fms-related tyrosine kinase 3), GATA3 (GATA binding protein 3), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), KDR (Kinase insert domain receptor), KEAP1 (Kelch Like ECH Associated Protein 1), KIT (KIT proto-oncogene, receptor tyrosine kinase), KMT2D (Lysine Methyltransferase 2D), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MAPK1 (Mitogen-activated protein kinase 1), MSH2 (MutS Homolog 2), MSH3 (MutS Homolog 3), MYC (V-myc avian myelocytomatosis viral oncogene homolog), MYCN (MYCN Proto-Oncogene BHLH Transcription Factor), NOTCH1 (Notch 1), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), PTEN (Phosphatase and tensin homolog), RB1 (RB Transcriptional Corepressor 1), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TERT (Telomerase Reverse Transcriptase), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), TSC2 (TSC complex subunit 2), UGT1A1 (UDP glucuronosyltransferase family 1 member A1), VHL (von Hippel-Lindau tumor suppressor), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
